Edmond DE Rothschild Holding S.A. Buys 23,010 Shares of BioNTech SE (NASDAQ:BNTX)

Edmond DE Rothschild Holding S.A. raised its position in BioNTech SE (NASDAQ:BNTX - Free Report) by 31.0% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 97,310 shares of the company's stock after acquiring an additional 23,010 shares during the period. Edmond DE Rothschild Holding S.A.'s holdings in BioNTech were worth $11,088,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Charles Schwab Investment Management Inc. increased its stake in BioNTech by 123.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company's stock valued at $15,919,000 after purchasing an additional 74,119 shares in the last quarter. SG Americas Securities LLC increased its position in shares of BioNTech by 412.3% during the fourth quarter. SG Americas Securities LLC now owns 41,470 shares of the company's stock worth $4,726,000 after acquiring an additional 33,375 shares in the last quarter. Mirabaud & Cie SA acquired a new stake in shares of BioNTech in the 4th quarter worth about $684,000. Redmile Group LLC bought a new position in BioNTech in the 3rd quarter valued at about $18,345,000. Finally, Bank of New York Mellon Corp boosted its stake in BioNTech by 4.3% during the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock valued at $419,000 after purchasing an additional 150 shares during the last quarter. Institutional investors own 15.52% of the company's stock.

BioNTech Stock Performance

BNTX traded down $3.96 during trading hours on Friday, hitting $88.05. The stock had a trading volume of 1,035,719 shares, compared to its average volume of 843,634. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49. The company's fifty day simple moving average is $108.81 and its 200 day simple moving average is $112.80. The stock has a market cap of $21.13 billion, a PE ratio of -41.93 and a beta of 1.07. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

Remove Ads

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.70. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company's revenue was down 19.5% on a year-over-year basis. During the same quarter last year, the company earned $1.90 earnings per share. Equities analysts anticipate that BioNTech SE will post -3.88 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on BNTX. Truist Financial started coverage on BioNTech in a report on Friday, January 10th. They issued a "buy" rating and a $172.00 target price on the stock. Citigroup assumed coverage on shares of BioNTech in a research note on Thursday, March 13th. They issued a "buy" rating and a $145.00 target price for the company. HC Wainwright dropped their price target on shares of BioNTech from $150.00 to $145.00 and set a "buy" rating on the stock in a research report on Tuesday. Wells Fargo & Company assumed coverage on shares of BioNTech in a research report on Wednesday, December 11th. They issued an "overweight" rating and a $170.00 price objective for the company. Finally, Morgan Stanley dropped their target price on shares of BioNTech from $145.00 to $139.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $143.44.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.